Vivasure Medical, a Galway-based medical technology company, has been acquired by Haemonetics Corporation in a deal valued at up to €185 million. This acquisition will enable Haemonetics to scale Vivasure’s innovative PerQseal technologies, which focus on minimally invasive vessel closure.
The announcement was made on March 15, 2023. Vivasure Medical, established in 2009 and supported by Enterprise Ireland, has developed the PerQseal device. This technology offers a method for sealing blood vessels from the inside, enhancing procedures in fields such as cardiology, interventional radiology, and vascular surgery.
Currently, the use of PerQseal and its advanced version, PerQseal Elite, is not authorized in the United States. However, Vivasure has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for the PerQseal Elite vascular closure system, which is intended for arterial procedures.
Leadership Comments on Acquisition
Following the announcement, Andrew Glass, CEO of Vivasure Medical, expressed pride in the company’s advancements in closure technology. He noted, “We’re extremely proud of the progress made in advancing closure technology, and grateful to the clinicians who supported Vivasure’s mission. Joining Haemonetics provides the global scale and resources to accelerate the availability of PerQseal Elite and bring its clinical benefits to more physicians and patients worldwide.”
Co-founder and COO Ger Brett also highlighted the dedication of Vivasure’s employees and founders, saying, “We want to thank the Vivasure employees and founders for their dedication and commitment. We also want to recognise the board, investors, and government bodies for their phenomenal support over the years. We’re proud to make PerQseal in Ireland and distribute it around the world.”
Investment Background and Future Prospects
In 2022, Haemonetics made a strategic investment in Vivasure, which included an option to acquire the company. The following year, in 2023, Vivasure received an additional funding boost of €30 million from Haemonetics to further develop its vessel closure technology.
This acquisition marks a significant step for both companies, positioning Haemonetics to expand its product offerings and enhance the global reach of Vivasure’s innovative technologies. As the healthcare landscape increasingly shifts towards minimally invasive procedures, the integration of these technologies could greatly benefit patients and healthcare providers alike.
